The American Heart Association (AHA) recently held its annual meeting in Chicago, USA, and published many remarkable studies! According to Reuters and Bloomberg, a clinical trial of diabetes drugs, DECLARE research, lasted for an average of four years and accepted as many as 65,438+07,000 patients, including those without cardiovascular disease, which made the related treatment evaluation and future treatment recommendations more complete.
Reducing the death rate or hospitalization rate 17% is helpful for doctors to control the heart failure of sugar friends.
For decades, diabetes doctors have been focusing on lowering blood sugar to a certain target value. But diabetes is very likely to produce complications, such as myocardial infarction, optic neuropathy, nephropathy and so on. Among them, heart failure has serious consequences, and the survival rate after five years is only 50%. Therefore, how to control diabetes and cardiovascular risk at the same time is the focus of doctors and patients.
The results of this study were published in the United States and also in the New England Journal of Medicine. Studies have confirmed that compared with placebo, diabetic SGLT2 inhibitors reduce the hospitalization rate or death risk of heart failure 17%, and also reduce the risk of kidney disease, which undoubtedly provides a new perspective for the treatment of diabetes.
Expand the use of SGLT2 inhibitors to benefit more sugar lovers.
Danilo Verge, senior director of cardiovascular and metabolism at the pharmaceutical company that developed SGLT2, said, "More than half of the hospitalized patients with heart disease died within five years, which is equivalent to cancer. 」
Dr Stephen Wiviott, a senior researcher at Brigham and Women's Hospital, pointed out that this new discovery has made great progress in the use of SGLT2, which can help doctors understand how to prescribe drugs. In the past, this drug was used for patients with heart disease. According to the research results, Wiviott said that this new research data will help to expand the use of SGLT2 inhibitors and treat more patients, instead of many previous trials only for patients with confirmed heart disease.
Join us and pay attention to your health every day! Line @ ID: @ Subscribe to Health ALOHO audio-visual channel to read health knowledge more easily: /beauty/article/40294 Keywords: SGLT2 inhibitor, American Heart Association, diabetes, myocardial infarction, optic neuropathy, nephropathy.